Evaluating any hyperpigmentation treatment requires understanding how botanical blends perform against standard clinical benchmarks. Prescription depigmenting agents offer potent clinical outcomes, yet their side-effect profile makes them unsuitable for long-term or unsupervised intimate application.
| Depigmenting Compound | Mechanism of Action | Average Clinical Window | Primary Safety Risk |
|---|---|---|---|
| Hydroquinone (2%, 4%) | Direct melanocyte cytotoxicity & tyrosinase inhibition | 4, 8 weeks | Exogenous ochronosis, severe irritation |
| Amaira Blend (Mulberry / Bearberry) | Enzymatic tyrosinase suppression & antioxidant scavenging | 8, 16 weeks | Allergic contact dermatitis, mild desquamation |
| Kojic Acid (Pure 1%, 2%) | Copper chelation within tyrosinase active site | 6, 12 weeks | Sensitization, contact eczema |
| Cysteamine (5%) | Inhibition of tyrosinase & peroxidase enzymes | 8, 12 weeks | Sulfur odor, burning sensation |
